Eldon C. Mayer III - 11 Mar 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
Ex VP & Chief Commerc. Officer
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
11 Mar 2022
Net transactions value
$0
Form type
4
Filing time
11 Mar 2022, 20:06:45 UTC
Previous filing
11 Jan 2022
Next filing
14 Mar 2022
SEC
View on sec.gov

Key filing fact

Eldon C. Mayer III filed Form 4 for Eiger BioPharmaceuticals, Inc. on 11 Mar 2022.

Key facts

  • This page summarizes Eldon C. Mayer III's Form 4 filing for Eiger BioPharmaceuticals, Inc..
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 11 Mar 2022, 20:06.

Change

  • Previous filing in this sequence was filed on 11 Jan 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

EIGR transaction

Common Stock

Award

Transaction value
$0
Shares
+16,000
Change %
+35%
Price
$0.000000
Shares after
62,125
Date
11 Mar 2022
Ownership
Direct
Footnotes
F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

EIGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+98,000
Change %
Price
$0.000000
Shares after
98,000
Date
11 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
98,000
Exercise price
$5.10
Footnotes
F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022.
F2 The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .